Optimizing percutaneous coronary revascularization in diabetic women: Analysis from the EPISTENT trial

L. Cho, S. P. Marso, D. L. Bhatt, E. J. Topol

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Clinical studies have demonstrated that diabetic women have an increased risk of death and nonfatal myocardial infarction (MI) after percutaneous coronary intervention (PCI). However, there have been few data regarding the outcome of diabetic women in the current era of percutaneous coronary revascularization. Using the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial (EPISTENT) database, we determined morbidity and mortality for diabetic women undergoing PCT in the current era using stents and the glycoprotein IIb/IIIa inhibitor, abciximab. There were no mortality differences in the diabetic women treated with stent-placebo, stent-abciximab, or balloon-abciximab at 30 days and 6 months. However, the primary end point of 1-year death, MI, or target vessel revascularization (TVR) was lowered in the diabetic women from 34.5% in the stent-placebo group and 28.9% in the balloon-abciximab group to 13.3% in the stent-abciximab group (p = 0.02 for stent-stent comparison, and p = 0.09 for stent-abciximab vs. balloon-abciximab comparison). Also, 1-year TVR rates were lowered from 21.1% in the stent-placebo group and 26.7% in the balloon-abciximab group to 4.5% in the stent-abciximab group (p = 0.02 for stent-stent comparison, and p = 0.004 for stent-abciximab vs. balloon-abciximab comparison). The combination of stenting and abciximab therapy among diabetic women resulted in a significant reduction in 1-year rate of death, MI, or TVR compared with stent-placebo or balloon-abciximab therapy.

Original languageEnglish (US)
Pages (from-to)741-746
Number of pages6
JournalJournal of Women's Health and Gender-Based Medicine
Volume9
Issue number7
DOIs
StatePublished - 2000

Fingerprint

Percutaneous Coronary Intervention
Stents
Blood Platelets
Placebos
Myocardial Infarction
abciximab
Mortality
Platelet Glycoprotein GPIIb-IIIa Complex

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Optimizing percutaneous coronary revascularization in diabetic women : Analysis from the EPISTENT trial. / Cho, L.; Marso, S. P.; Bhatt, D. L.; Topol, E. J.

In: Journal of Women's Health and Gender-Based Medicine, Vol. 9, No. 7, 2000, p. 741-746.

Research output: Contribution to journalArticle

@article{803cb11298b544998f5226655406ae9c,
title = "Optimizing percutaneous coronary revascularization in diabetic women: Analysis from the EPISTENT trial",
abstract = "Clinical studies have demonstrated that diabetic women have an increased risk of death and nonfatal myocardial infarction (MI) after percutaneous coronary intervention (PCI). However, there have been few data regarding the outcome of diabetic women in the current era of percutaneous coronary revascularization. Using the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial (EPISTENT) database, we determined morbidity and mortality for diabetic women undergoing PCT in the current era using stents and the glycoprotein IIb/IIIa inhibitor, abciximab. There were no mortality differences in the diabetic women treated with stent-placebo, stent-abciximab, or balloon-abciximab at 30 days and 6 months. However, the primary end point of 1-year death, MI, or target vessel revascularization (TVR) was lowered in the diabetic women from 34.5{\%} in the stent-placebo group and 28.9{\%} in the balloon-abciximab group to 13.3{\%} in the stent-abciximab group (p = 0.02 for stent-stent comparison, and p = 0.09 for stent-abciximab vs. balloon-abciximab comparison). Also, 1-year TVR rates were lowered from 21.1{\%} in the stent-placebo group and 26.7{\%} in the balloon-abciximab group to 4.5{\%} in the stent-abciximab group (p = 0.02 for stent-stent comparison, and p = 0.004 for stent-abciximab vs. balloon-abciximab comparison). The combination of stenting and abciximab therapy among diabetic women resulted in a significant reduction in 1-year rate of death, MI, or TVR compared with stent-placebo or balloon-abciximab therapy.",
author = "L. Cho and Marso, {S. P.} and Bhatt, {D. L.} and Topol, {E. J.}",
year = "2000",
doi = "10.1089/15246090050147718",
language = "English (US)",
volume = "9",
pages = "741--746",
journal = "Journal of Women's Health",
issn = "1540-9996",
publisher = "Mary Ann Liebert Inc.",
number = "7",

}

TY - JOUR

T1 - Optimizing percutaneous coronary revascularization in diabetic women

T2 - Analysis from the EPISTENT trial

AU - Cho, L.

AU - Marso, S. P.

AU - Bhatt, D. L.

AU - Topol, E. J.

PY - 2000

Y1 - 2000

N2 - Clinical studies have demonstrated that diabetic women have an increased risk of death and nonfatal myocardial infarction (MI) after percutaneous coronary intervention (PCI). However, there have been few data regarding the outcome of diabetic women in the current era of percutaneous coronary revascularization. Using the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial (EPISTENT) database, we determined morbidity and mortality for diabetic women undergoing PCT in the current era using stents and the glycoprotein IIb/IIIa inhibitor, abciximab. There were no mortality differences in the diabetic women treated with stent-placebo, stent-abciximab, or balloon-abciximab at 30 days and 6 months. However, the primary end point of 1-year death, MI, or target vessel revascularization (TVR) was lowered in the diabetic women from 34.5% in the stent-placebo group and 28.9% in the balloon-abciximab group to 13.3% in the stent-abciximab group (p = 0.02 for stent-stent comparison, and p = 0.09 for stent-abciximab vs. balloon-abciximab comparison). Also, 1-year TVR rates were lowered from 21.1% in the stent-placebo group and 26.7% in the balloon-abciximab group to 4.5% in the stent-abciximab group (p = 0.02 for stent-stent comparison, and p = 0.004 for stent-abciximab vs. balloon-abciximab comparison). The combination of stenting and abciximab therapy among diabetic women resulted in a significant reduction in 1-year rate of death, MI, or TVR compared with stent-placebo or balloon-abciximab therapy.

AB - Clinical studies have demonstrated that diabetic women have an increased risk of death and nonfatal myocardial infarction (MI) after percutaneous coronary intervention (PCI). However, there have been few data regarding the outcome of diabetic women in the current era of percutaneous coronary revascularization. Using the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial (EPISTENT) database, we determined morbidity and mortality for diabetic women undergoing PCT in the current era using stents and the glycoprotein IIb/IIIa inhibitor, abciximab. There were no mortality differences in the diabetic women treated with stent-placebo, stent-abciximab, or balloon-abciximab at 30 days and 6 months. However, the primary end point of 1-year death, MI, or target vessel revascularization (TVR) was lowered in the diabetic women from 34.5% in the stent-placebo group and 28.9% in the balloon-abciximab group to 13.3% in the stent-abciximab group (p = 0.02 for stent-stent comparison, and p = 0.09 for stent-abciximab vs. balloon-abciximab comparison). Also, 1-year TVR rates were lowered from 21.1% in the stent-placebo group and 26.7% in the balloon-abciximab group to 4.5% in the stent-abciximab group (p = 0.02 for stent-stent comparison, and p = 0.004 for stent-abciximab vs. balloon-abciximab comparison). The combination of stenting and abciximab therapy among diabetic women resulted in a significant reduction in 1-year rate of death, MI, or TVR compared with stent-placebo or balloon-abciximab therapy.

UR - http://www.scopus.com/inward/record.url?scp=0033809567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033809567&partnerID=8YFLogxK

U2 - 10.1089/15246090050147718

DO - 10.1089/15246090050147718

M3 - Article

C2 - 11025866

AN - SCOPUS:0033809567

VL - 9

SP - 741

EP - 746

JO - Journal of Women's Health

JF - Journal of Women's Health

SN - 1540-9996

IS - 7

ER -